Rutgers’ principal investigator for the Moderna phase 3 coronavirus vaccine clinical trial at Rutgers New Jersey Medical School is available to discuss the drugmaker’s submission of its vaccine to the U.S. Food and Drug Administration for regulatory approval.

“It is exciting that the Moderna coronavirus vaccine has shown to be 94 percent effective in preventing symptomatic disease and 100 percent effective in preventing severe disease with no serious safety concerns identified till date,” said Shobha Swaminathan, an associate professor at Rutgers NJMS and medical director of infectious diseases practice at University Hospital in Newark. “We’re optimistic that the data, along with those from other vaccines and therapeutic interventions will help mark the beginning of the road to recovery from this pandemic.”  



Rutgers Biomedical and Health Sciences (RBHS) takes an integrated approach to educating students, providing clinical care and conducting research, all with the goal of improving human health. Aligned with Rutgers University–New Brunswick, and collaborating university-wide, RBHS includes eight schools, a behavioral health network and four centers and institutes. RBHS offers an outstanding education in medicine, dentistry, pharmacy, public health, nursing, biomedical research and the full spectrum of allied health careers. RBHS clinical and academic facilities are located throughout the state.